Voltar
Revisão Acesso aberto Revisado por pares
BIBTEX RIS

An updated patent review on PD-1/PD-L1 antagonists (2022-present)

2024; Taylor & Francis; Volume: 34; Issue: 8 Linguagem: Inglês

10.1080/13543776.2024.2368237

ISSN

1744-7674

Autores

Wiktor Uzar, B.Z. Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera‐Mularz, Radosław Kitel,

Tópico(s)

CAR-T cell therapy research

Resumo

PD-L1, via its interactions with PD-1, constitutes a key immune checkpoint that allows cancer cells to escape immune surveillance. Targeting PD-1/PD-L1 with monoclonal antibodies (mAbs) led to spectacular success in clinical oncology. However, the inherent limitations of mAbs and increasing findings about immune-related adverse events (iRAEs) prompted intense research in the field of small-molecule inhibitors of PD-L1.

Referência(s)